Company Directory / biotech/health
PrivateFor profitbiotech/healthChina
Haihe Biopharma
Haihe Biopharma is a biopharmaceutical company that develops cancer anti-tumour drugs.
- Founded
- 2011 15 years ago
- Staff
- 251-500 band, as listed
- Followers
- - on LinkedIn
- Funding
- $318M as listed, currency not stated
Set against six million companies
Size
251-500 people: larger than 92% of companies with a size listed
Age
15 years old.
Reach
Website ranked #10,384,130 in the world for traffic, about 233 visits a month.
What it does
BiopharmaBiotechnologyHealth CareMedicalPharmaceutical
Funding, as listed
$318M currency not stated
- Rounds2
- LatestSeries b, Jul 2020
- Investors19, 2 leading
What the source datasets report. We have not watched these rounds ourselves.
Every detail we hold
Everything the source datasets list about Haihe Biopharma, field by field. Contact details are held but never shown.
The company
- Name
- Haihe Biopharma
- Type
- For profit
- Status
- Private
- Founded
- 2011
- Founders
- Jian Ding
- Industry
- biotech/health
- Categories
- Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical
Where
- Country
- China
- Markets
- Asia-Pacific (APAC)
Size and reach
- Staff band
- 251-500
- Web traffic rank
- #10,384,130
- Monthly web visits
- 233
Funding, as listed
- Total
- 317,605,942 (currency not stated)
- Rounds
- 2
- Latest round
- Series b
- Latest round date
- Jul 2020
- Investors
- 19
- Lead investors
- 2
- Listing status
- private
About this record
- Sources
- Crunchbase
- Last imported
- Sept 2026
Growth, as the source summarises it
Haihe Biopharma may be growing as it has recently entered into an agreement with another company for the distribution of a new lung cancer medicine, which suggests an expansion of its product reach and potential revenue streams. This deal is indicative of the company's active role in the biopharmaceutical industry and its efforts to commercialize its research. Additionally, the overall biopharmaceuticals contract manufacturing market, which is relevant to Haihe Biopharma's operations, is projected to grow significantly, reaching USD 31.92 billion by 2032, implying a favorable market environment for the company's growth.
Summaries written by the source dataset, not by us, and not checked.
Companies like it
biotech/health in China.
From the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 38,667 companies in China and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.